Rare Disease Day Summit highlights myositis and the 7000 other rare diseases affecting one in ten Americans COLUMBIA, MD, UNITED STATES, February 27, 2025 /EINPresswire.com/ — The Myositis Association (TMA), in collaboration with the Myositis International Health and Research Collaborative Alliance (MIHRA) and Nori’s Fight, will host, We Care for Rare Summit: Celebrating Myositis Science…
Continue Reading
On Monday, February 10, 2025, Rich DeAugustinis, Vice Chair of TMA’s Board of Directors, testified to the Georgia Senate Committee on Health and Human Services in support of the Georgia Hope for Patients Act (S.B. 72). This proposed legislation, sponsored by Georgia Senator Matt Brass, will allow patients who have severely debilitating or life-threatening illnesses to…
Continue Reading
By Paula Eichenbrenner, TMA Executive Director and Laurie Boyer, TMA Board of Directors Chair At TMA, we believe research is the key to better treatments and a brighter future for those living with myositis. Our mission includes an important commitment to “fund innovative myositis research.” In fact, TMA has invested nearly $10 million into research…
Continue Reading
The Myositis Association (TMA) recognizes that the best hope for a cure for myositis diseases lies in research. Since 2002, TMA’s annual research grants program has approved 68 projects totaling nearly $8.2 million to study the underlying causes and natural progression of myositis, develop better treatments and more effective therapies, and ultimately to create a cure…
Continue Reading
Since 2002, The Myositis Association’s annual research funding program has awarded nearly $8.2 million in research support. We are pleased to announce our 2024 grant awards, funding disease-specific projects in myositis: Our first grant of $80,000 is awarded to Thomas Lloyd, MD, PhD, Chief of Neurology at Baylor College of Medicine, Houston, TX, for his…
Continue Reading